It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Place of pitavastatin in the statin armamentarium: promising evidence
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14804

Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus



Review

(10562) Total Article Views


Authors: Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K

Published Date May 2011 Volume 2011:5 Pages 283 - 297
DOI: http://dx.doi.org/10.2147/DDDT.S13492

Yasuyuki Kawai, Ryoko Sato-Ishida, Atsushi Motoyama, Kouji Kajinami
Department of Cardiology, Kanazawa Medical University, Uchinada, Japan

Abstract: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery disease prevention. However, there are considerable issues regarding statin safety and further development of residual risk control, particularly for diabetic and metabolic syndrome patients. Pitavastatin is a potent statin with low-density lipoprotein (LDL) cholesterol-lowering effects comparable to those of atorvastatin or rosuvastatin. Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism. Considering these factors along with its unique pharmacokinetic properties, which suggest minimal drug–drug interaction, pitavastatin could provide an alternative treatment choice, especially in patients with glucose intolerance or diabetes mellitus. Many clinical trials are now underway to test the clinical efficacy of pitavastatin in various settings and are expected to provide further information.

Keywords: HMG-CoA reductase inhibitor, pitavastatin, efficacy, safety, diabetes mellitus


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.